From: Progress in adjuvant chemotherapy for breast cancer: an overview
Recurrence risk category and definition | Recommended regimens: ER-positive, HER2-negative | Recommended regimens: ER/PR-negative, HER2-negative | Recommended regimens: HER2-positive |
---|---|---|---|
Very low risk | |||
• Node-Neg, T1a | No chemotherapy | No chemotherapy | No chemotherapy |
Low risk | |||
• Node-Neg, T1b | Consider second generation chemotherapy regimen if RS is high | Consider second generation chemotherapy regimen | Consider weekly paclitaxel + H |
• Node-Neg, T1c, | Second generation chemotherapy regimen if RS is high (or consider if intermediate) | Second generation chemotherapy regimen | Weekly paclitaxel + H or TCH |
Moderate risk | |||
• Node-Neg, T2 | Second or third generation chemotherapy regimen if RS intermediate-high | Third generation chemotherapy regimen | AC-T + H or TCH +/− P |
High risk | |||
• 1+ Pos Nodes or T3 | Third generation chemotherapy regimen if RS intermediate-high (or 4+ positive nodes irrespective of RS) | Third generation chemotherapy regimen | AC-T + H or TCH+/−P |